BREAKING NEWS

BeyondSpring announces submission of New Drug Application (NDA) to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN).
Read more

NEWS & MEDIA

We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.

PRESS RELEASES

BeyondSpring Files 2019 Annual Report on Form 20-F

BeyondSpring Files 2019 Annual Report on Form 20-F April 30, 2020 NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...

read more

MEDIA

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.